Hello and good morning!
 

We’ve been keeping a thrilling secret, and now we can finally spill the beans!
 

Our in-depth research into Lantern Pharma Inc. (Nasdaq: LTRN) has uncovered some game-changing results. The company is buzzing with strong pre-market energy, leading to an impressive bump. 🌟 

Don’t miss out—check them out now!

Why Lantern Pharma Looks So Good:
 

✨ Stunning Clinical Trial Results:

• The Phase 2 HARMONIC™ trial has shown an 86% clinical benefit rate.

• Significant tumor size reductions and stable disease control, positioning their treatment as a game-changer in NSCLC.

(2)

🧐 Positive Analyst Buzz:

A top analyst is eyeing an $18 target, hinting at a potential 400% upside. Excitement is building around Lantern Pharma’s prospects. (1)(8)

(8)

💡 Exciting Preclinical Breakthrough:

• Lantern Pharma’s LP-184 shows synergy with checkpoint inhibitors, resensitizing tumors non-responsive to Anti-PD1 therapy. (9)

• In collaboration with MD Anderson, LP-184 transforms “cold” tumors into “hot” ones, enhancing immunotherapy effectiveness. (9)

• This supports Lantern’s AI-driven hypothesis and is in Phase 1 trials for advanced solid tumors. (9)

🤖 Cutting-Edge AI Technology:

• Lantern Pharma uses their AI platform, RADR®, to revolutionize drug discovery, slashing costs and speeding up development. (5)

• This innovative approach leads to impressive clinical outcomes and positions them at the forefront of oncology. (5)
 

🌍 Major Regulatory Wins:

• Recent approvals in Japan and Taiwan will boost patient enrollment and data collection. (7)

• These milestones enhance their clinical findings and underscore their global impact. (7)
 

📗 Attractive Market Potential:

• With the latest news, Lantern Pharma’s technical indicators are looking stronger than ever. (1)

• As a low float company, their shares have significant movement potential. (2)(3)

(1)

💯 Recent Achievements:

• Molecular Diagnostic Milestone: Advancing a diagnostic tool for LP-184, enhancing patient selection in trials. (6)

• Japanese Patent: Securing a patent for LP-284, strengthening their development and partnership opportunities. (6)(7)
 

Implications and Potential:

Lantern Pharma is transforming cancer treatment with their AI-driven approach and groundbreaking clinical results. Their advancements promise new, effective options for patients and a bright future in oncology.
 

Keep a close eye on Lantern Pharma Inc.’s (Nasdaq: LTRN) journey. 

This is a company you will want to watch closely!

‼️ ATTENTION ‼️ 

We’re moving to a new WhatsApp Community! Stay in the loop with Market Tips by joining us at the link below:

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. bit.ly/46BqY7S
2. https://finance.yahoo.com/quote/LTRN/
3. https://finance.yahoo.com/quote/LTRN/history/
4. https://www.businesswire.com/news/home/20240805396240/en/
5. https://www.businesswire.com/news/home/20240509849518/en/
6. https://www.businesswire.com/news/home/20240710249401/en/
7. https://www.businesswire.com/news/home/20240612787863/en/
8. on.mktw.net/4dz3d2V

9. https://finance.yahoo.com/news/lantern-pharma-highlights-promising-preclinical-133100920.html

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and LFG Equities, Momentum Media LLC has been hired for a period beginning on 08/07/2024 and ending on 08/08/2024 to publicly disseminate information about (LTRN:US) via digital communications. We expect to be paid fifty thousand dollars USD. We own zero shares of (LTRN:US).